A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 9, 2009, Pages 1042-1048

  Mantzaris, Gerassimos J ^a,c   Viazis, Nikolaos ^a   Petraki, Kalliopi ^b   Papamichael, Konstantinos ^a   Theodoropoulos, Ioannis ^a   Roussos, Anastassios ^a   Karakoidas, Christos ^a   Koilakou, Stavroula ^a   Raptis, Nikolaos ^a   Smyrnidis, Alexandros ^a   Agalos, George ^a   Karamanolis, Dimitrios G ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

^b METROPOLITAN HOSPITAL   (Greece)

^c GHA 'Evangelismos'   (Greece)

Author keywords

Azathioprine; Crohn's disease; Hydrocortisone; Infliximab; Loss of response

Indexed keywords

ANTIBODY; AZATHIOPRINE; CORTICOSTEROID; HYDROCORTISONE; INFLIXIMAB;

ADD ON THERAPY; ADULT; AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INFUSION REACTION; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOMODULATION; JAUNDICE; LABORATORY TEST; LIVER TOXICITY; MAINTENANCE THERAPY; MALE; PANCREATITIS; PATIENT COMPLIANCE; PILOT STUDY; PLATELET CELL COUNT; PREMEDICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; WHOTE BLOOD CELL COUNT;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; HYDROCORTISONE; MIDDLE AGED; PILOT PROJECTS; PREMEDICATION; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 69549110671     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32832937e3     Document Type: Article

References (22)

1. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present D, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337:1029-1035. (Pubitemid 27430520)
2. Present DH, Rutgeerts P, Targan S, Hanauer S, Mayer L, van Hogezand L, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340:1398-1405. (Pubitemid 29205403)
3. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer L, Schreiber S, Colombel J, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002; 359:1541-1549. (Pubitemid 34621118)
4. Sands BE, Anderson FH, Bernstein CN, Chey W, Feagan B, Fedorak R, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350:876-885. (Pubitemid 38252535)
5. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128:862-869. (Pubitemid 40523539)
6. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371:660-667.
7. Vermeire S, Van Assche G, Rutgeerts P. Review article: Altering the natural history of Crohn's disease-evidence for and against current therapies. Aliment Pharmacol Ther 2007; 25:3-12. (Pubitemid 44902859)
8. Infliximab: summary of product characteristics. Malvern, Pa: Centocor, 17 January 2002.
9. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-Infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008; 103:944-948.
10. Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006; 63:433-442. (Pubitemid 43261469)
11. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56:1226-1231. (Pubitemid 47300423)
12. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348:601-608. (Pubitemid 36204954)
13. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126:1593-1610. (Pubitemid 38649876)
14. Farrell R, Alsahli M, Jeen Y, Falchuk KR, Peppercorn MA, Michetti P, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124:917-924. (Pubitemid 36389794)
15. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44:265-267. (Pubitemid 46175082)
16. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134:1861-1868. (Pubitemid 351790744)
17. Lichtenstein GR, Diamond RH, Wagner C, Olson A, Hegedus R, Bala M, Sandborn WJ. Infliximab administered as 3-dose induction followed by scheduled maintenance therapy in IBD: comparable clinical outcomes with or without concomitant immunomodulators [abstract]. Gastroenterology 2007; 132:A-146.
18. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70:439-444.
19. Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, et al. European Crohn and Colitis Organization. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006; 55 (Suppl 1):i1-15.
20. D'Haens G, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114:262-267. (Pubitemid 28093532)
21. STSC PLUS*WARE software product. Stagraphics user's guide. Rockville, MD: STSC; 1986.
22. Mantzaris GJ, Roussos A, Kalantzis CH, Koilakou S, Raptis N, Kalantzis N. How adherent to treatment with azathioprine are patients with Crohn's disease in long-term remission? Inflamm Bowel Dis 2007; 13:446-450.